When I was diagnosed with Parkinson’s in August 2019, a doctor told me that Sinemet (Levodopa/Carbidopa), the starter drug of ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

The origin of many diseases such as Alzheimer's or Parkinson's can be found at the molecular level in our body, in other ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Certain cancers and Parkinson's disease are especially difficult to treat, because many of the disease relevant proteins are ...

KinCon biolabs, a spin-off from the University of Innsbruck, is expanding its patented platform technology to support ...